CONSUN PHARMACEUTICAL GROUP LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.67 HKD | -0.87% |
|
+5.00% | +18.87% |
| Sales 2023 | 2.59B 357M 2.8B | Sales 2024 * | 2.94B 406M 3.18B | Capitalization | 4.16B 575M 4.5B |
|---|---|---|---|---|---|
| Net income 2023 | 785M 108M 848M | Net income 2024 * | 928M 128M 1B | EV / Sales 2023 | 1.33 x |
| Net cash position 2023 * | 2.19B 303M 2.37B | Net cash position 2024 * | 2.87B 396M 3.1B | EV / Sales 2024 * | 0.44 x |
| P/E ratio 2023 |
4.42
x | P/E ratio 2024 * |
4.6
x | Employees | 3,127 |
| Yield 2023 * |
5.72% | Yield 2024 * |
6.67% | Free-Float | 42.31% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -0.87% | ||
| 1 week | +5.00% | ||
| Current month | +1.25% | ||
| 1 month | -0.70% | ||
| 3 months | +7.18% | ||
| 6 months | +25.17% | ||
| Current year | +18.87% |
1 week
5.51
5.75
1 month
5.355.87
Current year
4.675.99
1 year
4.315.99
3 years
2.928.00
5 years
2.618.00
10 years
2.619.75
| Managers | Title | Age | Since |
|---|---|---|---|
Meng An
CEO | Chief Executive Officer | 52 | 21-03-23 |
Pei Cheng Fang
DFI | Director of Finance/CFO | 45 | 10-07-31 |
Han Xing Xu
BRD | Director/Board Member | 30 | 20-10-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Quan Zhu
BRD | Director/Board Member | 84 | 12-12-23 |
Zhong Shi Feng
BRD | Director/Board Member | 65 | 13-12-01 |
Yu Jun Chen
BRD | Director/Board Member | 44 | 13-04-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +2.28% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 5.67 | -0.87% | 1 077 800 |
| 24-04-25 | 5.72 | +1.60% | 674,500 |
| 24-04-24 | 5.63 | +0.54% | 667,000 |
| 24-04-23 | 5.6 | +0.54% | 365,310 |
| 24-04-22 | 5.57 | -0.18% | 710,000 |
Delayed Quote Hong Kong S.E., April 26, 2024 at 04:08 am EDT
More quotes
Consun Pharmaceutical Group Limited is an investment holding company principally engaged in the manufacture and sale of pharmaceuticals. The pharmaceutical products of the Company include kidney medicines, contrast medium and others. The Companyâs subsidiaries include Brilliant Reach Group Limited, Century International Develop Limited and Grand Reach Company Limited. Through its subsidiaries, the Company is also engaged in the research and development of pharmaceutical products.
Sector
Pharmaceuticals
Calendar
2024-08-21
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
5.249
CNY
Average target price
7.272
CNY
Spread / Average Target
+38.54%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +18.87% | 580M | |
| +19.62% | 43.78B | |
| +20.44% | 21.89B | |
| +10.86% | 14.45B | |
| +13.07% | 13.63B | |
| +37.46% | 11.49B | |
| -8.59% | 6.85B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +6.35% | 5.06B |
- Stock Market
- Equities
- 1681 Stock
